Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
Georgina V. Long(The University of Sydney), Caroline Robert(Institut Gustave Roussy), Brian J. Sharkey(Bristol-Myers Squibb (United States)), Ian M. Waxman(Apple (Israel)), Célèste Lebbé(Inserm), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Catalin Mihalcioiu(McGill University Health Centre), Catriona M. McNeil(Chris O’Brien Lifehouse), Cornelia Mauch(University Hospital Cologne), Henrik Schmidt(Aarhus University Hospital), Jessica C. Hassel(German Cancer Research Center), Micaela Hernberg(Apple (Israel)), Ewa Kalinka‐Warzocha(Apple (Israel)), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Laurent Mortier, J. Charles(Apple (Israel)), Helen Gogas(National and Kapodistrian University of Athens), Benjamin Brady(Apple (Israel)), Christine E. Horak(Bristol-Myers Squibb (United States)), Kerry J. Savage(Spinal Cord Injury BC), Victoria Atkinson(Greenslopes Private Hospital), Michele Maio(University of Siena)
Cited by 53
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k